Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nantkwest Inc CS (NK)

Nantkwest Inc CS (NK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve...

MOTS : 0.0004 (-50.00%)
NK : 32.49 (+14.89%)
IBRX : 5.10 (+1.29%)
ImmunityBio and NantKwest Complete Merger

ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing...

NK : 32.49 (+14.89%)
IBRX : 5.10 (+1.29%)
Stockholders of NantKwest Approve Merger With ImmunityBio

NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the...

NK : 32.49 (+14.89%)
ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

ImmunityBio, Inc. , a privately-held immunotherapy company, and NantKwest, Inc. ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of...

NK : 32.49 (+14.89%)
SHAREHOLDER ALERT: Barr Law Group Investigating NK, IQDNX, JELD, and MDXG; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Infinity Q Diversified Alpha Fund,...

NK : 32.49 (+14.89%)
JELD : 10.75 (+2.48%)
MDXG : 9.20 (-0.22%)
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”),...

NK : 32.49 (+14.89%)
ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

ImmunityBio, Inc ., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to...

NK : 32.49 (+14.89%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger Investigation

WILMINGTON, Del., Feb. 20, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

NK : 32.49 (+14.89%)
CATM : 39.01 (+0.08%)
LCYAU : 13.14 (+1.38%)
CRSA : 8.81 (-3.40%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, CLGX, SYNC, NK; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

MDCA : 5.42 (-3.39%)
CLGX : 80.00 (+0.59%)
SYNC : 2.19 (-0.45%)
NK : 32.49 (+14.89%)
ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

ImmunityBio, Inc., a privately-held immunotherapy company, today announced the oral presentation of “ Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle...

NK : 32.49 (+14.89%)

Barchart Exclusives

How to Invest for Kids: Understanding the Basics
A good way to show kids the value of compounding money is to ask if they’d rather have a $100 bill today or a penny that doubles every day for 30 days. They will be surprised to hear that in 30 days, that penny would be worth about $5.4 million dollars! Here's a guide to the types of accounts you can open for your children or grandchildren. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar